Clinical trial · Observational
A Prospective Observational Study on of Early-Onset Gastrointestinal Cancer: From Tumor Features to Patient Lifestyle Habits
A Prospective Observational Study on of Early-Onset Gastrointestinal Cancer: From Tumor Features to Patient Lifestyle Habits - YOGICO Study
NCT07479472CI-TRIAL-00105789YOGICOnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The YOGICO study aims to characterize the distinctive features of EoGI cancer through a holistic approach that integrates clinical and demographic data, tumor biological characteristics, and patient lifestyle habits
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Early-onset Gastrointestinal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| to characterize the distinctive features of EO-GI cancer through a comprehensive approach that considers clinical and demographic factors, tumor features, and patient lifestyle habits | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- EoGI cancer patients newly diagnosed
- interventionNames
- Other: to characterize the distinctive features of EO-GI cancer through a comprehensive approach that considers clinical and demographic factors, tumor features, and patient lifestyle habits
Primary outcomes (1)
- measure
- Primary outcome
- timeFrame
- One year from the enrollment
- description
- Describe clinical and tumor features of newly diagnosed EoGI cancer patients in a real-world Italian setting.
Secondary outcomes (4)
- measure
- Secondary outcome measure
- timeFrame
- Six and twelve months follow-up
- description
- EoGI cancer type of treatment at diagnosis (chemotherapy, immunotherapy, targeted therapy, surgery, radiotherapy or best supportive care); progression of disease (if any) and survival status at 6 and 12 months follow-up.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 49 Years
Show eligibility criteria text
Inclusion Criteria: * Provide a signed and dated informed consent form (ICF) * Willing to comply with all study procedures and be available for the duration of the study * Male or female, aged 18-49 years old at time of EoGI cancer diagnosis * Patients with newly diagnosed early-onset gastrointestinal cancer histologically confirmed: colorectal, gastroesophageal and pancreatic tumor site, regardless of histological type * Any disease stage, performance status, and type of treatment, including experimental therapies and supportive care * Previous or concomitant malignancies are allowed provided they do not involve the gastrointestinal tract Exclusion Criteria: * Cognitive, linguistic, or physical barriers that prevent a detailed reconstruction of the patient's personal medical history including past lifestyle habits * Having previously received any treatments directed at the newly diagnosed EOGI cancer (i.e., at the time of inclusion, the patient has not yet started any type of treatment, excluding surgery)
References
Publications (0)
Data not yet available
No reference posted for this study.